NCT02379416View on ClinicalTrials.gov

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 13, 2015

Primary Completion Date

June 27, 2026

Study Completion Date

June 27, 2026

Conditions
Solid Tumors
Interventions
DRUG

Nilotinib + Paclitaxel

The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH